Arcturus Therapeutics Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arcturus Therapeutics Ltd.
Five $1bn+ alliances were penned in November. Topping the list was a potential $4.5bn deal between Arcturus Therapeutics and CSL Seqirus.
The firm’s live-virus COVID-19 vaccine candidate BriLife is entering a late-stage study following Phase II success, sparking hopes that its spontaneous mutations could parallel those of VOCs.
A new global clinical trial initiative is assessing a number of second-generation candidate vaccines for COVID-19. The Australian medicines regulator has given the go-ahead for an approval application for one of the vaccines, from Taiwan’s Medigen.
In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Alcobra Ltd.
- Alcobra Pharma
- Arcturus Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.